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Abstract
Preclinical studies using genetically engineered mouse models (GEMMs) have the potential to 
expedite the development of effective new therapies; however, they are not routinely integrated 
into drug development pipelines. GEMMs may be particularly valuable for investigating 
treatments for less common cancers, which frequently lack alternative faithful models. Here we 
describe a multi-center cooperative group that has successfully leveraged the expertise and 
resources from philanthropic foundations, academia, and industry to advance therapeutic 
discovery and translation using GEMMs as a preclinical platform. This effort, known as the 
Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments 
for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no 
effective treatments for NF1 and few promising approaches on the horizon. Since 2008 
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participating labs have conducted 95 preclinical trials of 38 drugs or combinations through 
collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 
therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities 
and challenges of building this type of consortium and highlights how it can accelerate clinical 
translation. We believe that this strategy of foundation-academic-industry partnering is generally 
applicable to many diseases and has the potential to markedly improve the success of therapeutic 
development.
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Introduction
Approximately 90% of potential anti-cancer therapies fail in early clinical trials (1). This 
dismal statistic underscores the need to better predict efficacy before drugs are tested in 
humans. While GEMMs are beginning to inform clinical trials, they are not routinely 
integrated into most drug development pipelines. From an industry perspective the reasons 
for this include the complex network of proprietary and commercial rights surrounding 
GEMMs, the expense associated with maintaining large animal colonies, and the lack of 
comprehensive data illustrating that GEMMs are superior to xenografts for predicting 
efficacy. These issues become even more complex when combining drugs from different 
companies. Academic laboratories, on the other hand, have pioneered the development of 
GEMMs but are often unable to perform rigorous in vivo preclinical studies due to barriers 
including prohibitive costs, inaccessibility to proprietary compounds, and the need to focus 
on “innovative (individual) science” to ensure academic success. While these problems are 
applicable to testing drugs for common cancers, developing treatments for rare tumor types 
is even more challenging.
One population affected by these challenges are individuals with the familial cancer 
syndrome neurofibromatosis type 1 (NF1). Accordingly, in 2008 the Neurofibromatosis 
Preclinical Consortium (NFPC) was established. This effort, originally conceptualized and 
funded by the Children’s Tumor Foundation (CTF) and later co-funded by the CTF and the 
Neurofibromatosis Therapeutic Acceleration Program (NTAP), was designed to support 
preclinical translational research and facilitate collaborative studies between academic labs 
and pharmaceutical companies, using GEMMs of NF1-associated tumors. Since its 
inception the NFPC has established a robust structure for conducting preclinical testing, 
identified multiple new therapeutic targets, and directly advanced clinical translation. Here 
we review our experience with the expectation that elements of this approach can be used as 
a template to accelerate the development of therapies for other neoplasms and human 
disorders.
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NF1: Background and Mouse Models
Neurofibromatosis type 1 (NF1) is a cancer predisposition syndrome with an incidence of 1 
in 3500 (2). Affected individuals can develop benign and malignant tumors that arise in 
diverse tissues. The NF1 gene also more broadly functions as a tumor suppressor in sporadic 
cancers including glioblastoma, melanoma, leukemia and lung cancer (3). NF1 encodes a 
GTPase activating protein (GAP) that negatively regulates Ras by accelerating GTP 
hydrolysis (4). As such, Ras and its downstream kinases become aberrantly activated when 
NF1 function is lost. However, despite an extensive understanding of Ras signaling networks 
and the availability of compounds that target various Ras effectors, there are currently no 
effective treatments for cancers with RAS or NF1 mutations.
GEMMs that recapitulate distinct NF1-associated tumor types have been developed. The 
most common tumors, neurofibromas, affect the peripheral nervous system and occur in 
50% of individuals with NF1 (2). While these tumors are benign they can be painful, 
debilitating, disfiguring, and lethal. Internal tumors, termed plexiform neurofibromas (PN), 
can progress to malignancy. Neurofibromas are histologically complex. While NF1-deficient 
Schwann cell precursors drive tumor development (5), these lesions are also comprised of 
nerves, macrophages, fibroblasts, mast cells, and Schwann cells (4). Accordingly, cell line 
models do not accurately recapitulate the cellular complexity of neurofibromas and patient-
derived xenografts do not exist. Fortunately, two Cre-lox based GEMMs are used by 
consortium members (5, 6). This tumor type illustrates how GEMMs may be essential for 
preclinical studies. Importantly, these models have now been shown to predict both clinical 
successes and failures.
The most common malignancies associated with NF1 are Malignant Peripheral Nerve 
Sheath Tumors (MPNSTs) (2). These cancers emanate from plexiform neurofibromas, but 
also develop spontaneously in individuals with and without NF1. MPNSTs are lethal in 
approximately 70% of cases. A GEMM that develops tumors indistinguishable from human 
MPNSTs has been developed (7, 8). This model harbors compound mutations in Nf1 and 
p53 but also relies on the spontaneous loss of wild-type alleles. It is used by consortium 
members because it carries the hallmark genetic alterations of human MPNSTs, and because 
it recapitulates the high stochastic mutational load of human tumors, thus permitting the 
evaluation of immunotherapies.
Finally, consortium members also study GEMMs that recapitulate juvenile myelomonocytic 
and acute myeloid leukemia (JMML and AML). Because mutations in NF1 or KRAS also 
occur in sporadic myeloid diseases, Cre-lox based models that incorporate these alterations 
have been developed (9, 10). Studying these models in parallel allows for the evaluation of 
targeted agents in benign versus malignant disease and also permits a comparison of 
responses in NF1 versus KRAS mutant tumors. Altogether, the NFPC is currently comprised 
of investigators studying two models of PN (5, 6), MPNST (7), JMML and AML (9, 10). In 
all instances these strains faithfully recapitulate the genetic, biochemical, cell biologic, and 
pathologic features of the corresponding human tumors. Additional GEMMs were 
considered, but legal issues at some institutions precluded integration into the consortium.
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Benefits of the NFPC Structure
In addition to having robust GEMMs in hand, the initial design of the NFPC structure also 
contributed to its success. The NFPC was developed with three essential components: (1) 
academic scientists with expertise in NF1 and mouse models; (2) an External Advisory 
Board (EAB) comprised of scientists from pharmaceutical and biotechnology companies, 
NF1 clinicians, and individuals with expertise in legal affairs; and (3) a Project Manager 
(PM). Because NFPC laboratories study different tumors, an initial goal was to evaluate the 
same drugs across models. Taking this approach early on yielded several benefits. First, 
laboratories rapidly shared information regarding drug formulation and administration, 
maximally tolerated doses (MTD), and toxicities. Second, standard operating procedures 
(SOPs) were developed for collecting, processing, and analyzing pharmacodynamic 
endpoints. Finally, this parallel analysis permitted the assessment of the same target in 
models of early (e.g. PN and JMML) versus late (e.g. MPNST and AML) stage tumors. This 
concerted effort not only enhanced the speed at which the group learned how to execute 
rigorous preclinical trials, but also demonstrated that agents exert different effects in distinct 
tumor types.
The EAB initially advised academic sites in conducting trials according to industry 
standards with respect to sample size, endpoints, and pharmacokinetic profiling. Academic 
labs have now developed additional productive interactions with scientists in industry, which 
offers insight into compound handling, formulation, and permits the comparison of GEMM 
data with prior experience in xenograft models. Thus, partnering with industry adds value 
that extends well beyond simply obtaining drugs for testing. Finally, the PM coordinates 
NFPC activities, oversees the implementation of SOPs, maintains relationships with industry 
partners, and serves as a scientific liaison to supporting philanthropic organizations, thereby 
enabling a “center without walls”.
Addressing Legal Issues in Industry-Academic Partnerships
To facilitate material transfer agreements (MTAs) a Contracting Collaborative Group was 
established that consisted of contracting offices from each academic institution, the PM, and 
CTF legal counsel. While this structure facilitated complex negotiation processes, MTA 
agreements frequently remain a rate-limiting step. Pharmaceutical companies have complex 
approval processes and are justifiably wary of risk that could arise with molecules in active 
clinical development. On the other side, academic institutions are protective of potential 
intellectual property rights. The Supreme Court ruling in Merck v. Integra broadened the 
permissibility to make or use patented material for research that would “contribute relatively 
directly to the FDA approval of a drug”, and opened the door to synthesizing and testing 
compounds without industry agreements. Despite this, the NFPC seeks to develop 
collaborative relationships whenever possible. In our experience, the benefits of directionally 
sharing information and expertise generally outweigh the drawbacks of cumbersome MTA 
processes. Nevertheless, increased flexibility and willingness to compromise on the part of 
companies and academic institutions would facilitate future efforts of this nature.
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Conducting Preclinical trials Using Industry Standards
NFPC studies are conducted using industry practices. This includes implementing group-
wide SOPs, determining the MTD in tumor-bearing mice, and standardizing 
pharmacodynamic (PD) and pharmacokinetic (PK) analyses. SOPs contain detailed drug 
formulation protocols, drug delivery methods, schedules and doses, and details for PK and 
PD sample collection and processing. Our experience supports establishing the MTD in each 
model as we have observed substantial variability across strain backgrounds and in healthy 
versus tumor-bearing mice.
Kinetic PK/PD studies have led to important practical and mechanistic insights. Tissue 
samples are routinely collected from three mice per time-point at baseline and multiple time-
points after treatment. PK/PD are first assessed in wild-type strain-matched mice and a 
surrogate tissue (e.g. lung) is used to compare PD across different models, which has 
allowed NFPC investigators to predict efficacious drug doses based on the degree and 
duration of target inhibition across models and/or with related drugs. When possible, 
collaborating pharmaceutical companies perform PK analysis, which permits comparisons 
of drug exposure to prior studies in xenografts and correlations with tolerated doses in 
humans. As such, efficacy is either evaluated at the MTD or, preferably, at a dose that most 
closely reflects the tolerated human dose when known. This practice has greatly facilitated 
clinical translation.
Each GEMM differs with respect to phenotypic characteristics, rates of progression, and 
causes of death. For example, MRI-based comparisons of tumor burden is the primary 
endpoint in one PN model while survival is used in mice with AML. Therefore, it is 
essential to perform prospective power analyses and use relevant model-specific endpoints 
and cohort sizes for statistical analysis. After an endpoint for assessing efficacy is 
established in an individual model, it is applied consistently in sequential trials. This strategy 
allows NFPC investigators to compare the relative efficacy of different compounds within 
and across different tumor models.
Successful Target Identification and Translation
Tables 1 and 2 summarize the therapeutic targets that have been identified and the ongoing 
or planned clinical trials based on work performed by NFPC investigators. The following 
paragraphs describe a subset of the relevant preclinical studies that informed subsequent 
clinical trials.
Targeting Ras Effectors With Single Agents
Because aberrant Ras activation drives NF1-mutant tumors, NFPC members have 
extensively examined single agents that target various Ras effector kinases. One of the 
earliest agents evaluated was the “first generation” MEK inhibitor CI-1040 (Pfizer). While it 
was ineffective in Nf1-mutant JMML, it unexpectedly induced transient remissions in Nf1-
deficient AMLs (11). Based on these initial data, NFPC investigators systematically tested 
PD0325901 (PD901, Pfizer), which has superior PK properties and longer target inhibition. 
In JMML PD901 induced dramatic disease regression in the same model that was 
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unresponsive to CI-1040 (12), demonstrating that sustained pathway inhibition in vivo is 
essential for efficacy. Interestingly, genetic analysis of bone marrow cells revealed the 
persistence of Nf1 mutant cells, suggesting that MEK inhibition normalized the proliferation 
and differentiation of Nf1 mutant hematopoietic cells, but did not eradicate them. Similar 
effects were observed in the KrasG12D JMML model (13). Together, these preclinical studies 
directly informed the design of a clinical trial of the FDA-approved MEK inhibitor 
trametinib (GlaxoSmithKline) in JMML. Moreover these studies demonstrated the 
importance of measuring PK/PD and mutant allele burden in children enrolled on this trial.
MEK inhibition also exhibited efficacy in two mouse models of plexiform neurofibroma 
(PN) ((14) and unpublished data). Specifically, PD901 and selumetinib (Astra Zeneca) each 
induced tumor regression at clinically achievable doses. These studies inspired 4 ongoing 
clinical trials evaluating different MEK inhibitors (PD901, selumetinib, and trametinib) in 
NF1 patients with plexiform neurofibromas. In the first completed Phase 1 study, partial 
responses were observed in more than 70% of patients and regressions were maintained 
(15). This finding is unprecedented for these tumors, which are largely unresectable and 
currently untreatable, and prospective phase 2 studies are now underway.
Despite the promising activity of MEK inhibitors in early stage neoplasms, these agents only 
slightly attenuated MPNST growth in mice and Nf1-deficient AMLs became resistant (11, 
16). Moreover, in MPNSTs the mTORC1 inhibitor rapamycin exerted more potent effects 
than MEK inhibitors, albeit responses were still cytostatic (17, 18). These findings suggest 
that different NF1-mutant tumor types may be more or less dependent on different Ras 
effector pathways. In addition, it should be noted that while MEK inhibitors promoted 
neurofibroma regression in both mouse models and human clinical trials (14, 15), sirolimus 
did not induce regression in either mice or humans (19, 20). Thus, the comparable positive 
and negative effects of MEK and mTOR inhibitors on neurofibroma regression, respectively, 
illustrate the predictive value of these GEMMs.
Combination Trials
Given the large number of available therapeutic agents, mouse models represent a powerful 
tool for identifying the most promising combinations among numerous possibilities. This 
approach is further enhanced when guided by complementary basic scientific studies. For 
example, while MEK and various PI3K pathway inhibitors are ineffective as single agents in 
MPNSTs, MEK and mTORC1 inhibitors together cause potent tumor regression in GEMMs 
(16). Transcriptional profiling and imaging studies further identified the glucose transporter, 
GLUT1, and consequently 18F-FDG uptake as unique biomarkers of sustained (dual) 
inhibition of MEK and mTOR (16). These observations have directly informed the design of 
a clinical trial evaluating the efficacy of this combination and early FDG-PET imaging as a 
biomarker. A similar basic/preclinical approach, aimed at identifying other cancer-related 
vulnerabilities in MPNSTs, also led to the development of an ongoing clinical trial 
evaluating the effects of combined HSP90 and mTOR inhibitors ((21) and NCT01427946). 
As drug combinations will likely be required to confer maximal therapeutic responses in 
both benign and malignant tumors characterized by NF1 mutations, GEMMs will be 
essential for identifying the most promising combinations.
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Leveraging basic research to identify new therapeutic targets
A distinct advantage of this consortium model is the extensive (combined) expertise of 
academic investigators in studying this complex disease, which is fortified by ongoing basic 
studies. Thus, the academic nature of the NFPC represents both an intellectual and financial 
asset in this translational endeavor. For example, the neurofibroma model was used in an 
insertional mutagenesis screen to identify new effector pathways in NF1-mutant tumors. 
Using this approach a Stat3-Arid1b/β-catenin pathway was found to be essential for 
neurofibroma formation (22), supporting the investigation of JAK/STAT and Wnt/β-catenin 
pathway inhibitors as potential therapeutic agents. Human genetic and mouse modeling 
studies also identified the epigenetic regulator, SUZ12, as an important tumor suppressor in 
MPNSTs (23). Mechanistic studies further revealed that bromodomain inhibitors could 
effectively counteract the effects of SUZ12 loss, prompting a preclinical study to evaluate 
the effects of MEK and BRD4 inhibitors. When combined these agents triggered potent 
tumor regression of MPNSTs in vivo, thus revealing another promising therapeutic 
combination (23). This observation is currently being extended to investigate BRD4 and 
MEK inhibition in murine AMLs and neurofibromas.
Targeting the Tumor Microenvironment
Another advantage of GEMMs is that tumors develop with an intact microenvironment. This 
permits the evaluation of agents that target cancer cell-host interactions. Notably, genetic and 
cell biologic studies using GEMMs showed that infiltrating haploinsufficient bone marrow-
derived mast cells contribute to PN development (24). Because mast cells are critically 
regulated by c-KIT, the therapeutic effects of imatinib mesylate (Gleevec, Novartis) were 
evaluated. Treatment decreased tumor size and number by 50% and 25%, respectively. 
Based on these findings, a child with a life-threatening airway obstruction from an 
inoperable PN was treated on a compassionate use basis and responded dramatically (24). A 
subsequent phase 2 study using imatinib demonstrated responses in 25% of individuals and 
further suggested that neurofibromas located in the head and neck have the highest 
probability of responding (25). Additional trials are ongoing in this population with imatinib 
(NCT01140360, NCT02177825 and NCT01673009), and a broader trial is evaluating the 
effects of cabozantinib (Exelixis). Interestingly, while cabozantinib inhibits c-KIT, it also 
inhibits additional kinases, including MNK, a newly identified in MPNSTs that, when 
suppressed, synergizes with MEK inhibitors (26). Finally, macrophages are also important 
for the maintenance of plexiform neurofibromas (27). Specifically, the CSF1R/KIT inhibitor 
PLX3397 (Plexxikon) was shown to trigger macrophage depletion and neurofibroma 
regression in GEMMs and inspired the development of another ongoing clinical trial 
(NCT02390752). It is important to note that a critical feature of the NFPC is its collaborative 
culture, which fosters data sharing in real time, ultimately increasing the rate at which we 
discover, understand, and translate new therapies.
Identifying Additional Therapeutic Targets
Other studies by NFPC members have identified additional promising therapeutic targets in 
NF1 tumor models including EGFR (28), Aurora kinase A (29), HDAC, and PAK1 (30), 
with new candidates undergoing active investigation. Importantly, the NFPC offers a 
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powerful platform to rapidly evaluate these targets, new clinical drugs, and drug 
combinations. Because therapeutic development is an iterative and collaborative process, 
members of the NFPC and the Department of Defense-funded NF Clinical Consortium 
interact on a regular basis, both formally and informally. This bidirectional preclinical/
clinical pipeline facilitates the development of the most promising preclinical findings into 
mechanism-driven clinical trials and will enable clinical and laboratory investigators to work 
together to improve standard-of-care therapies as they emerge.
Summary
The NFPC experience demonstrates the feasibility of exploiting GEMMs in a multi-center 
setting that is reminiscent of human cooperative clinical trials networks. While throughput is 
lower than conventional xenografts, GEMMs accurately reflect the underlying disease in the 
appropriate environment and harbor an intact immune system. In principle, these attributes 
should improve predictive value, particularly when similar drug exposures can be achieved 
in mouse and humans. Moreover, the ability to rapidly assess agents can be exploited to 
identify the best clinical candidate against a specific therapeutic target, as well as the most 
promising drug combinations. The comparable therapeutic effects of MEK and c-KIT 
inhibitors observed in human and mouse neurofibromas, both illustrates and validates this 
approach.
Several principles have emerged from NFPC trials. First, the degree and duration of target 
inhibition are often critical factors dictating response. This observation underscores the 
value of performing PK/PD analysis in both the preclinical setting and in clinical trials. 
While the success of any trial may ultimately be dependent on whether sustained target 
inhibition in tumors can be achieved without toxicity, the duration of target inhibition is 
difficult to measure in humans. Therefore, GEMMs may be invaluable for developing 
tractable biomarkers of target inhibition and/or early efficacy. Second, parallel basic studies 
that elucidate mechanisms of tumor development and maintenance in vivo can fuel new 
therapeutic approaches. While in vitro drug screening strategies are important, unique 
insight can be gained by studying tumors in immunocompetent animals with an intact tumor 
microenvironment. Finally, the collaborative nature of this foundation-academic-industry 
partnership has unquestionably increased the speed of target identification and translation. 
This approach has obvious appeal for developing therapies for less common diseases, but 
can also be extended to therapeutic development in any tumor type for which accurate 
mouse models exist.
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Abbreviations
GEMMs genetically engineered mouse models
NFPC neurofibromatosis preclinical consortium
NF1 neurofibromatosis type 1
CTF children’s tumor foundation
NTAP neurofibromatosis therapeutic acceleration program
PN plexiform neurofibromas
MPNST malignant peripheral nerve sheath tumor
JMML juvenile myelomonocytic myeloid leukemia
AML acute myeloid leukemia
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Table 1
Clinical trials resulting from NFTC investigators
Drug Tumor Type Phase Clinical Trial
Imatinib Plexiform NF 2
2
2
NCT01140360
NCT02177825
NCT01673009
Selumetinib Plexiform NF 1
2
2
NCT01362803
NCT02407405
NCT02644512
Trametinib Plexiform NF ½ NCT00920140
Bevacizumab + Everolimus MPNST 2 NCT01661283
Ganetespib + Sirolimus MPNST ½ NCT01427946
PD0325901 Plexiform NF 2 NCT02096471
Trametinib JMML 2 In development
Cabozantinib Plexiform NF 2 NCT02101736
Nilotinib Plexiform NF 2 NCT01275586
PLX3397 Plexiform NF ½ NCT02390752
Selumetinib + Vistusertib MPNST ½ In development
BRD4i + MEKi MPNST, Plexiform NF ½ In development
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Table 2
Potential therapeutic targets identified as single agenta, in combinationb or in genetic studyc
Target Tumor Type Reference
1 mTORC1 MPNSTb (16, 21)
2 MEK Plexiform NFa, JMMLa, MPNSTb (12–14, 16)
3 STAT3 Plexiform NFc (22)
4 c-KIT Plexiform NFa,c (24)
5 BRD4 MPNSTb,c, Plexiform NFb, JMMLb (23)
6 eIF4E MPNSTc (16)
7 MNK MPNSTb,c (26)
8 VEGFR MPNSTb unpublished
9 HDAC MPNSTb unpublished
10 PI3K/p110α MPNSTa (16)
11 AKT Plexiform NFa, JMMLa unpublished
12 Hsp90 MPNSTb (21)
13 CSF1R Plexiform NFa (27)
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